An ancient war between humans and fae brought a terrible Curse to the land. Now the only two who can end the Curse are an untried young woman and an exiled warrior. They must battle High Fae, Deathsworn, and an immortal evil that threatens to devour the whole world… Learn more about this book series and author at http://bit.ly/UnfinishedSongSeries YA Fantasy
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
The National Inventors Hall of Fame and the United States Patent and Trademark Office (USPTO) will host the Greatest Celebration of American Innovation May 4-5. The two-day event will include the Induction of 16 innovation trailblazers into the Hall of Fame and the unveiling of the expanded National Inventors Hall of Fame Museum.
Mo Rocca, Emmy award-winning CBS Sunday Morning correspondent and Host of The Henry Ford’s Innovation Nation, will give the first official museum tour and serve as Master of Ceremonies for the 44th Annual National Inventors Hall of Fame Induction Ceremony. Participants will have the opportunity to be historians and visionaries as both events focus on honoring the past and inspiring the future.
To view the multimedia release go to:
http://www.multivu.com/players/English/7667851-national-inventors-hall-of-fame/
The Prostate Cancer Foundation is throwing a one-two punch to knock out prostate cancer for good with the recent production of a public service announcement featuring boxing legend and five-time heavyweight champion of the world Evander Holyfield. The message encourages African-American men to get regularly checked for prostate cancer because they are more than twice as likely to develop this disease than any other type of cancer.
To view the Multimedia News Release, go http://www.multivu.com/players/English/7545851-pcf-holyfield-prostate-cancer-psa/
In this darkly comedic road trip novel, seventeen year-old Vivian Apple returns home after the alleged "Rapture" to find her devout parents gone and two mysterious holes in the roof. Vivian never believed in the Rapture, or the uber powerful Church of America. Now that she has been left behind, Vivian's quest for the truth begins. Find out more at http://katiecoyle.tumblr.com/ YA
After successful exploration runs in 2013 and 2015 the Dutch polar cruise company Oceanwide Expeditions has announced two new expeditions to the Ross Sea in 2017. The ice-strengthened vessel “Ortelius” will be accommodated with helicopters for the two Antarctica cruises, sailing from the South-American continent to the Antarctic Peninsula, crossing the Polar Circle, further west to Peter I Island, sailing in the Bellingshausen sea along the ice-edge of “deep Antarctica” into the Ross Sea. The voyage continues to the uninhabited sub-Antarctic Campbell Island and ends after 32 days in New Zealand. The second cruise offers the same itinerary, but in reverse.
The Ross Sea Challenge
The Ross Sea region of Antarctica has always presented a dream but also a challenge to visit to explorers. The Ross Ice Shelf prevents a full seasonal operation and distances are enormous. Apart from the extremes, landing sites are still difficult to reach. “With the advantages of the “Ortelius” in combination with the use of helicopters, our travelers are having some great opportunities exploring Antarctica’s most fascinating sites”, says CEO Michel van Gessel.
To view the multimedia release go to:
http://www.multivu.com/players/English/7726051-oceanwide-expeditions-new-ross-sea/
Hennessy, the world’s best-selling Cognac, is proud to announce a first-ever collaboration with fashion house Opening Ceremony to celebrate an encounter of two cultures – “East Meets West” – with an X.O-inspired limited-edition collector’s piece. Available at openingceremony.com, the Hennessy X.O “East Meets West” Travel Bag by Opening Ceremony is inspired by co-founders’ Carol Lim and Humberto Leon’s heritage and world travels, with an aesthetic that blends tradition and heritage with modern elements. The stunning design perfectly holds the iconic shape of the Hennessy X.O bottle – the world’s original X.O Cognac and ultimate gift this holiday season.
To view the multimedia release go to:
https://www.multivu.com/players/English/8455051-hennessy-opening-ceremony-east-meets-west-collaboration/
Following the successful global market introduction of its resealable beverage can end two years ago, XOLUTION GmbH, headquartered in Munich, Germany, announces the next generation can end and a major increase of its production capacity for 2016 to meet the growing global demand for XO technology.
The XO system is a revolutionary solution for beverage cans that allows people to reseal a beverage can multiple times and enjoy it at their leisure. Unlike familiar beverage cans, which can only be opened once, XO equipped beverage cans have lids with an integrated plastic opening mechanism that allows the can to be re-closed and portioned for later consumption. When driving a car, doing sports, shopping - beverages stay perfectly fresh and carbonated – without spilling, dripping or allowing dirt and insects to go in the can!
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7428951-xo-resealable-beverage-can/
The following statement is being issued by Block & Leviton LLP, Finkelstein Thompson LLP and Green & Noblin PC regarding the Drywall Antitrust Litigation.
If you purchased Wallboard INDIRECTLY from one or more of the companies listed below, your rights may be affected by proposed Settlements
Proposed class settlements totaling $10.5 million have been reached with two Defendants in In re Domestic Drywall Antitrust Litigation, MDL No. 2437 and 13-MD-2437, pending in the U.S. District Court for the Eastern District of Pennsylvania.
If you purchased for end use wallboard manufactured and/or distributed by CertainTeed Gypsum, Inc., USG Corporation, United States Gypsum Company, New NGC, Inc., Lafarge North America, Inc., Eagle Materials, Inc., American Gypsum Company LLC, PABCO Building Products, LLC, TIN, Inc., or their subsidiaries (collectively, the “Defendants”), between January 1, 2012 and November 30, 2014, you may be a class member. “Wallboard” means paper-backed gypsum wallboard, also called drywall or plasterboard.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7449651-drywall-class-action-settlement/
The sixth annual Productive Innovation Index released by IDEA Pharma today, which ranks biopharmaceutical companies by their ability to successfully bring innovations to market, sees Johnson & Johnson top the industry for the fourth year running.
The Productive Innovation Index measures, scores and celebrates a company’s ability to deliver innovation to patients, by objectively evaluating performance data based on a rolling five year period (2010-2015), and operates on the premise: if you gave the same molecule to two different companies in early phase, which would make the best of it?
The success of the Janssen Pharmaceutical Companies of Johnson & Johnson and its consolidation of 1st place across the past four years’ rankings is driven largely by innovations in the field of oncology, immunology, neuroscience and cardiovascular/metabolism. Notable performers include Zytiga® (prostate cancer), Imbruvica® (chronic lymphocytic leukemia and mantle cell lymphoma (co-developed and co-marketed with Pharmacyclics, an AbbVie company)), Simponi®/Simponi Aria® (rheumatoid arthritis), Stelara® (psoriasis and psoriatic arthritis), Invega Sustenna® and Invega Trinza® (schizophrenia).
To view the multimedia release go to:
http://www.multivu.com/players/uk/7770851-johnson-and-johnson-tops-idea-pharma/
Con-way Truckload, a full truckload carrier and subsidiary of Con-way Inc. (NYSE: CNW) today launched a military appreciation campaign called True to the Troops with a ceremony held at the company’s headquarters in Joplin that included the unveiling of two of the company’s tractor-trailers wrapped with images honoring and recognizing our nation’s military.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7503451-con-way-true-to-the-troops/
https://youtu.be/gZKVPMI-p18 Email isn’t the most organized method for business communication. There are better alternatives that are more efficient. The problem with email is that it’s difficult to keep track of things. Project collaboration can easily result in one-hundred to two-hundred emails per day, thousands per week, and before you know it you’re spending three hours just looking for one attachment, you’re missing meetings, and you’re confused about the goals. Is there a better way? YES!
